Exicure (XCUR) Non-Current Deffered Revenue (2016 - 2022)
Exicure (XCUR) reported Non-Current Deffered Revenue of $9.0 million for Q2 2022, down 10.05% quarter-over-quarter from $10.0 million in Q1 2022.
Exicure (XCUR) Non-Current Deffered Revenue (2016 - 2022) Analysis & Trends
Exicure has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $9.0 million in Q2 2022.
- For the quarter ending Q2 2022, Non-Current Deffered Revenue changed N/A year-over-year to $9.0 million; the trailing twelve-month figure through Jun 2022 stood at $9.0 million (changed N/A YoY), and the FY2021 full-year result was $11.5 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2022 stood at $9.0 million, down from $10.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $16.9 million in Q3 2021, with the low at $3.0 million in Q4 2019.
- Historically, Non-Current Deffered Revenue has averaged $10.1 million across 3 years, with a median of $10.0 million in 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 9.04 Mn |
| Mar 31, 2022 | 10.05 Mn |
| Dec 31, 2021 | 11.51 Mn |
| Sep 30, 2021 | 16.93 Mn |
| Dec 31, 2019 | 2.96 Mn |
| Dec 31, 2016 | 1.03 Mn |